Cost

KFF’s 2026 employer survey reports new data on cost-sharing in employer-sponsored coverage, including hospital admission and outpatient surgery charges, deductibles, and affordability pressures facing workers and families. The findings add a current employer-market view of health care cost exposure that is distinct from Medicare and Medicaid payment policy updates. It is also different from the previously published consumer affordability post because it centers on employer plan design and enrollee cost-sharing trends.

CMS finalized the CY 2027 ESRD payment rule, updating Medicare payment for dialysis services and related care. The fact sheet highlights a dialysis base-rate increase, the incorporation of phosphate binder costs into the ESRD bundled payment, and other payment adjustment changes affecting providers and program spending. The rule is materially focused on kidney care payment policy rather than the broader Medicare payment and pricing items already covered.

KFF updated this brief with October 2026 polling on medical bills, skipped care, and affordability concerns, providing a current snapshot of how health care costs affect households. The findings focus on consumer experience and financial strain, which is materially different from previously published items centered on Medicare payment rules, Medicaid oversight, or administrative reforms. It is a timely public-interest update on cost burdens facing patients directly.

CMS released a fact sheet on a proposed rule that would require Health Insurance Exchanges to verify eligibility criteria before providing advance premium tax credits and cost-sharing reductions. The proposal directly affects when subsidy payments are made and is aimed at improving payment accuracy and program integrity in coverage affordability programs. Because the topic centers on pre-eligibility checks for Exchange subsidies rather than Medicare, Medicaid managed care, or pricing transparency, it is materially different from the titles already published.

This KFF chart collection updates federal actuaries’ projections for U.S. health spending growth and highlights expected trends across hospitals, prescription drugs, and out-of-pocket costs. It offers a forward-looking view of cost pressures affecting households and public programs, making it a distinct addition to the topic beyond prior posts on specific CMS payment rules or reports to Congress. The source is especially relevant for readers tracking broader national cost trends rather than a single policy change.

CMS released a fact sheet on a proposed rule that would reduce generic drug copayments from $1 to $0 for certain full-benefit dual eligibles in Part D and add pharmacy benefit manager accountability provisions. The proposal is directly relevant to beneficiary affordability and plan oversight, with a narrower focus than previous broad drug-cost or Medicare reform posts. If finalized, the change would eliminate a small but recurring out-of-pocket charge for some low-income enrollees.

MedPAC’s Payment Basics overview explains how accountable care organization payment systems work and how they shape Medicare spending incentives. The document serves as a concise policy reference on benchmark, shared savings, and related payment mechanics rather than announcing a new CMS rule. It is distinct from previously published broad Medicare reform coverage because it centers on the structure of ACO payment models themselves.

CMS posted the October 2026 quarterly OPPS addendum updating hospital outpatient payment rates and APC assignments. The addendum is a core reference for hospitals, clinicians, and analysts tracking how Medicare will pay for outpatient services beginning in October 2026. It is materially focused on current outpatient payment rate files rather than broader payment policy proposals already covered in prior posts.

CMS announced final changes to Transparency in Coverage rules intended to make healthcare prices and insurance coverage information easier for consumers to find, compare, and report. According to CMS, the rule strengthens disclosure of out-of-network payment information, improves access to personalized cost-sharing details, and standardizes data to support more usable pricing information. The update is framed as a cost-transparency measure aimed at helping patients better understand potential healthcare expenses.

In a report released October 1, 2026, HHS OIG said Medicare Advantage organizations and prescription drug plans paid $72 million over three years for services associated with excluded providers or individuals convicted of certain felonies. The report quantifies avoidable spending and highlights oversight gaps in screening and payment controls within Medicare Advantage and Part D. It adds a distinct cost angle beyond prior posts by focusing on improper payments tied to excluded or criminally disqualified actors.

An HHS OIG report published September 28, 2026 found that many independent organ procurement organizations did not meet Medicare requirements for reporting kidney transportation costs, and some did not transport organs in line with Medicare rules. The findings raise cost-accountability concerns because Medicare reimbursement depends on accurate reporting and compliance with transportation requirements. This is distinct from previously published cost stories because it focuses on transplant logistics, reimbursement integrity, and oversight of a specialized provider type.

In a September 24, 2026 report, HHS OIG found limitations in CMS’s process for checking the accuracy of state-submitted Medicaid managed care medical loss ratio data. Because medical loss ratio reporting helps show whether capitation payments are being spent on patient care rather than administration or profit, weaknesses in CMS review can affect oversight of public spending. The report is materially distinct from prior posts because it focuses on data validation and fiscal accountability in managed care reporting, not broader Medicaid demonstration or state control policies.

This September 24, 2026 HHS OIG data brief examines how CMS’s price-substitution policy, using 2024 average sales prices, affected Medicare Part B drug payments. The brief is directly relevant to drug cost containment because it measures how payment substitutions changed Medicare spending for Part B drugs. It differs from earlier published items by focusing narrowly on the payment impact of a specific Part B pricing policy rather than broader Medicare reforms or beneficiary out-of-pocket costs.

CMS announced preliminary 2027 Medicare payment rates for clinical laboratory services on September 21, 2026. The agency said the proposed rates would better align Medicare payments with private-payer prices under the clinical laboratory fee schedule and could save taxpayers an estimated $1 billion each year. The announcement focuses specifically on laboratory service pricing, making it distinct from broader previously covered Medicare payment and reform actions.

A KFF survey published September 15, 2026 highlights affordability and access problems faced by adults with multiple or serious health conditions. The findings cover medical bills, delayed or skipped care, medication underuse due to cost, and insurance denials, offering a patient-experience view of cost pressures rather than a federal payment policy announcement. That makes it distinct from previously published CMS- and MedPAC-focused cost coverage.

CMS released a proposed physician payment rule for 2026 that ties cost policy to broader payment reform, including accountable care incentives and updates to physician reimbursement. The agency says the proposal would help modernize payment while avoiding an estimated $2.38 billion in improper advanced alternative payment model incentive payments over 10 years. For cost watchers, the proposal is notable because it frames physician payment changes as both a budget issue and a lever for moving Medicare away from volume-driven care.

CMS proposed OPPS and ASC payment changes aimed at affordability for Medicare beneficiaries, with a focus on drug payment policy, site-of-care incentives, and lower out-of-pocket costs. The agency highlights 340B drug payment changes and projected savings for Medicare and taxpayers, alongside reforms intended to reduce incentives that can make hospital outpatient care more expensive. The proposal is significant on cost because it combines beneficiary affordability with federal savings and provider payment redesign.

CMS issued guidance signaling tighter oversight of budget neutrality for Medicaid section 1115 demonstrations. The move centers on constraining how demonstration spending is measured and justified, with direct consequences for both federal and state Medicaid costs. This is a meaningful cost development because it could limit financing flexibility that states have used to support higher spending under waiver authority.

CMS finalized changes to the No Surprises Act independent dispute resolution process that lower administrative fees and revise batching and transparency rules. While the rule mainly addresses insurer-provider payment disputes, its cost relevance lies in reducing administrative friction and fees tied to resolving out-of-network payment disagreements. The changes could affect system costs indirectly by altering how often disputes are filed and what they cost to pursue.

CMS proposed Medicaid managed-care financing and payment changes aimed at state directed payments, provider taxes, and spending growth. The agency says the proposal would curb financing practices it views as inflating federal Medicaid costs while tying payments more closely to quality. Cost implications are potentially large because the rule targets mechanisms many states use to raise provider payments and draw down federal funds.

CMS finalized its 2027 Payment Notice with lower Exchange user fees and other policy changes affecting individual-market affordability and oversight. The agency presents the rule as a cost-lowering measure that also addresses fraud and gives states more flexibility, with implications for premiums, administrative expenses, and coverage dynamics. For a cost-focused audience, the key issue is how marketplace fee and affordability policy can shape what enrollees and taxpayers pay.

MedPAC’s March 2026 report to Congress reviews Medicare payment adequacy, beneficiary cost burdens, spending trends, and reform options across major payment systems. It provides a cross-cutting baseline for understanding where Medicare costs are rising, how payment rates compare with provider costs, and what policy changes lawmakers could consider. The report is especially useful for comparing cost pressures across hospital, physician, post-acute, and other sectors rather than focusing on a single CMS rule.

MACPAC’s March 2026 report includes analysis of Medicaid payment policy for the home- and community-based services workforce, linking payment rates to access and long-term spending pressures. Although narrower than a full program financing review, it addresses how states can use payment policy to stabilize care delivery and affordability in long-term services and supports. The report is relevant to cost because workforce payment decisions can influence both near-term Medicaid spending and the availability of less institutional care settings.